FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to glucagon-like peptide-1 (GLP-1) analogue derivatives and pharmaceutically acceptable salts thereof, which have double agonist action on human glucagon-like peptide-1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor.
EFFECT: invention can be used for treating non-insulin-dependent diabetes, insulin-dependent diabetes, obesity and other related diseases.
22 cl, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
